Monte Rosa Therapeutics (NASDAQ:GLUE) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Monte Rosa Therapeutics (NASDAQ:GLUE) released its quarterly earnings results on Thursday. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06), FiscalAI reports. Monte Rosa Therapeutics had a negative return on equity of 52.22% and a negative net margin of 302.69%.The company had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million.

Monte Rosa Therapeutics Trading Down 2.1%

GLUE stock traded down $0.42 during mid-day trading on Friday, reaching $19.39. The company’s stock had a trading volume of 547,092 shares, compared to its average volume of 819,558. The stock has a market cap of $1.64 billion, a PE ratio of -13.10 and a beta of 1.62. Monte Rosa Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $25.77. The company’s 50 day moving average is $17.69 and its two-hundred day moving average is $17.40.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Zacks Research downgraded shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 4th. Guggenheim reduced their price target on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Piper Sandler restated an “overweight” rating and set a $37.00 price target (up from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Wells Fargo & Company reduced their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Finally, Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Monte Rosa Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $32.80.

Insider Buying and Selling at Monte Rosa Therapeutics

In other news, insider Philip Nickson sold 5,845 shares of the stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $17.69, for a total value of $103,398.05. Following the completion of the sale, the insider owned 55,000 shares of the company’s stock, valued at $972,950. This represents a 9.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Markus Warmuth sold 5,466 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the completion of the sale, the chief executive officer directly owned 613,471 shares of the company’s stock, valued at approximately $10,993,400.32. This trade represents a 0.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 37,150 shares of company stock worth $668,694. Insiders own 6.90% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

Several hedge funds have recently made changes to their positions in GLUE. AQR Capital Management LLC purchased a new stake in shares of Monte Rosa Therapeutics in the 1st quarter valued at approximately $1,065,000. Goldman Sachs Group Inc. grew its stake in shares of Monte Rosa Therapeutics by 122.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock valued at $1,652,000 after buying an additional 196,238 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Monte Rosa Therapeutics in the 1st quarter valued at approximately $76,000. Geode Capital Management LLC grew its stake in shares of Monte Rosa Therapeutics by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after buying an additional 120,098 shares during the period. Finally, American Century Companies Inc. grew its stake in shares of Monte Rosa Therapeutics by 301.4% in the 2nd quarter. American Century Companies Inc. now owns 403,045 shares of the company’s stock valued at $1,818,000 after buying an additional 302,639 shares during the period. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.